Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Immunotherapeutic regulation of the tumor microenvironment in prostate cancer patients is not understood. Most antibody immunotherapies have not succeeded in prostate cancer. We showed previously that high-ris...

Source: Journal of Translational Medicine - May 28, 2020 Category: Research Authors: Stephen T. Ryan, Jing Zhang, Danielle N. Burner, Michael Liss, Emily Pittman, Michelle Muldong, Ahmed Shabaik, Jason Woo, Nicole Basler, Jonathan Cunha, Shabnam Shalapour, Monica V. Estrada, Michael Karin, Karen Messer, Stephen Howell, Christopher J. Kane Tags: Research Source Type: research